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 Abstract: 
The efficient and effective selection of appropriate plants for investigative purposes in 
a drug discovery program is of crucial importance for a successful outcome.  A 
variety of approaches have been used by researches with varying levels of success.  A 
variety of different approaches to plant selection are discussed, including the 
ethnomedicinal approach, some ecological approaches and the use of combinatorial 
and computational methodologies. 
 
Key words: 
Biodiversity, targeted selection, ethnomedicine, drug discovery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Figure 1: Outline of Possible Approaches to the Discovery of New Drug Leads 
 
A review of the types of drugs used to treat the wide spectrum of both infectious and 
non-infectious diseases serves to highlight the essential role played by plant, marine 
and microorganism-based secondary metabolites.  Undoubtedly natural sources still 
represent a rich untapped resource for the discovery of new drugs.  The present lack 
of funding for natural products research in some parts of the world where this type of 
research is seen as ‘fishing’ and low citation numbers and relatively low impact 
factors of journals in the field make the area of research unpopular by some funding 
agencies and university administrators.  On the other hand, in parts of the world 
where numbers of publications, and not necessary quality, is used as an indicator of 
academic success, often the rush to publish (and to publish as many papers as possible 
from one plant), and lack of appropriate screening facilities hinders the thorough 
evaluation of compounds produced for potential pharmacological activity. Faced with 
such extensive biodiversity and limited resources, the choice of where to most 
effectively focus one’s attention becomes crucial.  The choice may be guided by past 
successes or perhaps by current innovations with potential to deliver future results.   
 
The success of natural product research has been well reviewed by many, including 
four thorough analyses of the contribution of natural products to approved therapeutic 
agents by Newman, Cragg and Snader in 1997 and 2003 [1, 2] and by Newman and 
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Cragg in 2007 and 2012 [3, 4].  During the period 1981 to 2010, 54% of all new 
approved drugs came from natural sources.  Of these 4% were natural products, 22% 
were derived from natural products, 13% were produced by total synthesis but the 
active chromophore was a natural product and 15 % were from a biological source 
such as a large protein or peptide isolated from an organism or cell line [4].  If only 
the small-molecule approved drugs are considered, then 6% were natural products, 
28% were derived from natural products and 16% were produced by total synthesis, 
where the pharmacophore was based on a natural product [4].  
 
The development of drugs from natural products comes at a significant time and 
financial cost.  It is estimated that on average the cost of getting a drug to market is in 
excess of $ 1 billion if post approval Phase IV costs and costs linked to approval on 
non US markets are taken into account [5]. The National Cancer Institute (NCI) 
screened around 200 000 extracts between 1955 and 1980 with limited success [6].  
This led to a reduction in focus on random screening until 1986, when, with the 
improvement of screening methods, the NCI started screening again.  By 1995, 40 
000 extracts had been prepared and 18 000 screened for activity.  The success rate 
was about 1% [6].  In contrast, however, combinatorial chemistry has resulted in only 
one approved drug (Sorafenib) in the public domain in the time period until 2010 [4].  
This does not, however, take away from the fact that combinatorial chemistry is 
highly effective as a tool for structural optimization of an active chemical skeleton 
[4]. Comparing compounds prepared by people to those produced by plants, the most 
striking difference is one of complexity.  Natural sources use enzymes to bring about 
chemical transformations, enabling very specific structural changes to be made to 
specific sites in a stereospecific manner resulting in a complex molecule [6].  Being 
able to tap into this source of chemical diversity in a meaningful and effective way is 
crucial to successful drug development.  
 
The factors influencing the selection of marine or microbial samples for evaluation 
are, in most cases, different from those directing the choice of plant material.  The 
marine environment provides a vast, largely untapped, source of biodiversity.  One of 
the primary challenges facing sample selection in a marine setting is one of 
accessibility – your choice is often decided by what you can physically access and, as 
such, work is more frequently carried out on organisms living close to the shore [7]. 
Sampling techniques often require specialized equipment and in many cases very 
small quantities of active compound are obtained requiring nanomolar structure 
determination [7].   
 
With approximately half of the 20 best–selling non-protein drugs based on natural 
products and with almost all of the currently used natural products being of terrestrial 
origin (Harvey 2000, in Monaster and Luesch 2011) [7], the identification of good 
methods to improve the successful selection of promising plant material remains 
crucial.  In the light of the significant differences in the challenges facing the choice 
of marine or microbial material as opposed to plant material for study, this paper will 
restrict its comments to the selection of plant material. 
 
Success in identifying a new biologically active plant-based natural product can be 
influenced firstly by a clever choice of plant to investigate or secondly by how 
quickly and effectively a random selection of plant extracts can be screened.  Each of 
these approaches has produced a level of success and many of the methods employed 
in plant selection are based on one or the other system.  The huge cost involved in 
both time and resources to screen vast numbers of randomly selected extracts, with 
the small success rate, has led many investigators to advocate selection based on 
various non-random approaches [8].  The various approaches that will be discussed 
are outlined in figure 1. 
 
The ethnomedicinal approach 
 
The ethnomedicinal approach has resulted in a number of success stories.  The 19th 
century saw scientists starting to isolate the active principle from medicinally used 
plants – the first notable success being quinine from Chinchona bark by Caventou and 
Pelletier [9].  Other pre-world war 2 successes include morphine and codeine from the 
opium poppy, digoxin from Digitalis leaves and atropine (produced from (-)-
hyoscyamine) from Solanaceae species [9].  Tiotropium is currently being used to 
treat chronic obstructive pulmonary disease and is a derivative of atropine [10].  More 
recent years have seen cancer therapy impacted by natural products.  The most 
notable perhaps, being the derivatives of camptothecan and the diterpene, taxol.  
Camptothecan was isolated from Campotheca acuminate Decne., a tree widely used 
in Chinese traditional medicine, which resulted in its inclusion in the National Cancer 
Institute screening program [10].  In contrast, several samples of Taxus brevifolia 
were randomly collected for analysis by the National Cancer Institute.  The discovery 
of taxol was seen as serendipitous, but the tree has been used by West-American 
Indian groups for stomach complaints among other things and the Tsimshian (from 
British Columbia) use it to treat cancer [10]. 
 
Galanthamine, isolated from the Russian species Galanthus woronowii Losinsk. Was 
discovered through an ethnobotanical lead and is currently being used to treat 
Alzheimer’s disease [10]. 
 
The decision to investigate a particular plant species is very often determined by the 
fact that the plant is already being used for some purpose, possibly medicinally or as 
an insect repellent or for some cultural purpose.  This would constitute an 
ethnobotanical approach to plant selection and would apply to a vast number of 
phytochemical investigations.  The testing of the plant extracts and any isolated 
compounds can be guided by what the plant is traditionally used for and any positive 
results would serve to validate the use of the plant as well as provide useful leads for 
further drug development.  
 
The ethnomedicinal approach allows for an increased possibility of finding an active 
compound as well as a means of documenting and preserving local knowledge.  This 
becomes of greater importance with the increased mobility among rural communities 
and the subsequent loss of local knowledge of the use of indigenous plant species 
[11]. Two important issues need to be addressed in regard to the ethnomedicinal 
approach to plant selection.  Firstly the rights of the country of origin with respect to 
any drugs discovered need to be protected, as outlined in the United Nations 
Convention on Biological Diversity [12]. Secondly the quality of any 
ethnopharmacological field studies carried out prior to plant selection is important, 
and may have an impact on the success of the research [13].  Thorough 
ethnopharmacological field studies can lay a vital platform from which the 
phytochemical investigation of a plant species can be launched.  
 
The development of ethnobotanical databases can provide valuable information to aid 
in plant selection for investigation.  An example of this is a regional database 
detailing the 1672 uses (medicinal, ceremonial, veterinary) of 474 plant species in the 
Campania region of Italy compiled by De Natale et al. [14].  The researchers gathered 
the information from various historical sources, including diaries, travel accounts and 
treatises on medicinal plants over the last three centuries and noted that 50 plant 
species were continuously used over this time to treat the same ailments.  A similar 
historical study was carried out by Giogetti et al. [15] on Brazilian plants used in 
relation to the central nervous system.  A survey of historic books in various San 
Paulo libraries revealed thirty-four plant species, thirteen of which are also used by 
modern Brazilian communities.  Only eight species have been studied from a 
pharmacological perspective.  Perry et al. have similarly looked at historically used 
plants, mainly in Europe, to treat memory loss and Alzheimer’s disease [16].  In 
addition to historical sources, databases of plant uses have been established by 
recording self-reported practices of local people.  An example of this is the database 
started by Karunamoorthi et al. documenting the use of plants as insect-repellents in 
the Western Hararghe region of Ethiopia [17].  Lehman et al. [18] developed a 
systematic matrix that they used to compile a database of potential leads for pest 
management in Mali.  Their criteria included traditional medicinal use; antimicrobial 
activity and insect defense activity and their information was gathered from the 
literature and interviews with local farmers, healers and scientists. Such databases can 
serve as a useful ethnobotanical starting point to plant selection for further testing and 
investigation. Hutchings et al.’s book on Zulu traditional plants [19], for example, has 
provided the basis of much work into plants used by the Zulu people. 
 
Comprehensive field studies and the establishment of ethnomedicinal databases can 
provide valuable resources to those wishing to select promising plants for study.  
Statistical analysis of the sometimes vast databases of medicinally used plants has 
been successfully used to identify families of plants that are over- or underused by 
traditional practitioners.  Regressional analysis [20], contingency table and binomial 
analyses [21] as well as  Baysian and Imprecise Dirichlet Model (IDM) approaches 
[22, 23] have been used.   Regression analysis has been used to analyse the SANBI 
Medlist Database of southern African medicinally used plants [20], contingency table 
and binomial analyses to investigate the Ecuadorian Shuar medicinal flora [21] and 
the medicinal flora of Campania, Italy has been analysed by the Baysian, binomial 
and IDM methods [22, 23].  These studies all demonstrated a clear bias for particular 
families in each of the regions investigated and, as such, could be used to guide the 
choice of plants to be studied. 
 
The value of the ethnomedicinal approach to plant selection may be determined by its 
successes and failures.  A small number of studies will be mentioned here in this 
regard.  Khafagi and Dewedar in 2000 and Gyllenhaal et al. in 2012 each directly 
compared the activity of plants collected randomly in a particular region with those 
selected in an ethnomedicinally-directed manner [24, 25].  Khafagi and Dewedar 
screened sixty plants growing wild in Sinai, Egypt for antibacterial and antifungal 
activity.  Thirty-six were selected randomly and twenty-four were selected as the 
Bedouins in the region use them for their antibacterial or antifungal properties.  
Fifteen of the thirty-six randomly selected plants showed activity against some of the 
bacterial and fungal strains tested while twenty of the twenty-four ethomedicinally-
selected plants showed activity (41.7% versus 83.3%) [24].  Gyllenhaal et al. 
compared plants randomly selected from the Cuc Phuong National Park in Vietnam 
with a selection of plants used by traditional healers of Laos and Vietnam.  Two types 
of samples were investigated: ‘samples’, a single part of a plant species collected in a 
particular region and ‘collections’ which could contain more than one part of the 
plant, collected in a specific region.   All extracts were screened for 
antimycobacterial, antiplasmoidal, chemopreventative and anticancer activity.  The 
results were not overwhelmingly in favour of an ethnomedicinal approach to plant 
selection.  Over the whole range of tests, the randomly selected ‘collections’ were 3% 
more likely to give a positive result than those ethnomedicinally selected.  With 
‘samples’, the ethnomedicinally selected extracts were 6% more likely to give a 
positive result [25].   
 
A large number of papers have been published reporting positive activity over a wide 
range of tests for plant extracts chosen using ethnomedicinal criteria.  In many cases 
the active principal is isolated and identified, but the value is mostly in verifying the 
efficacy of the plant rather than the isolated active compound being developed further 
into a registered drug.  The ethnomedicinal approach has successfully been used by 
the researchers at Shaman Pharmaceuticals to verify the use of Cryptolepsis 
sanguinolenta (Lindl.) as a treatment for type II diabetes as well as a basis for the 
isolation of the active component, the alkaloid, cryptolepine [26, 27].  C. 
sanguinolenta is used by traditional healers in Ghana to treat symptoms of type II 
diabetes, including fungal infections, pain and inflammation [26].  
 
Cryptolepine and its hydrochloride salt possess a range of well-documented biological 
activities, including antimicrobial, antibacterial, antiinflammatory, antihypertensive, 
antipyretic, antimuscarinic, antithrombotic, noradrenergic receptor antagonistic and 
vasodilative properties as well as being used as an effective antimalarial agent [26].  
Both the dichloromethane and hot water extracts of the ground roots of C. 
sanguinolenta demonstrated the ability to lower blood glucose in a non-insulin-
dependent diabetes mellitus mouse model.  In vivo-guided fractionation, using the 
same model resulted in the isolation of cryptolepine  as the active ingredient [26, 27].  
A small study was conducted using 20 women newly diagnosed with type II diabetes.  
Plasma glucose levels decreased immediately after administration of the plant extract 
(ground roots boiled in water, 20mL of extract given four times a day, equivalent to 
0.11 mg/kg body weight/day).  Mean glucose level of 16.6 mmol/L reduced  to 4 
mmol/L) [27].  Such studies demonstrate the possibilities of using the ethnomedicinal 
approach, both in verifying the use of a particular plant to treat a particular disease, 
but also in the isolation of the active ingredient.  Haddad et al. [28] evaluated plants 
traditionally used by the Cree Indians of Canada’s Eastern James Bay for treating type 
II diabetes and its related symptoms.  Their investigation found good correlation 
between those plants highly rated by healers and those showing good activity (glucose 
lowering, low toxicity and minimal complications) over a range of in vitro and in vivo 
tests.  
 
One of the greatest health problems in Africa today is malaria.  The increase in drug 
resistant strains of malaria and the limited number of affordable chemoprophylactic or 
chemotherapeutic agents makes the development of new antimalarial agents of 
significant importance.  The most commonly used antimalarial drugs are of plant 
origin or are derived from compounds of plant origin (the quinoline-based alkaloids 
and artemisinin and its derivatives) [29].  Of the 700 taxa used to treat malaria and/or 
fever, 134 were selected using weighted criteria (the taxon’s association with malaria, 
documented antiplasmodial potential of the plant family, its use by traditional healers, 
whether it occurred in a malaria-endemic area and its popularity in the local plant 
markets).  This resulted in 49% of the plant extracts tested showing good activity 
(IC50< or = 10g/mL) and 17% being highly active (IC50< or = 5g/mL) [29]. 
 
A further application of the ethnomedicinal approach is to make cross-cultural 
comparisons of plant families or genera used for various diseases.  Saslis-Lagoudakis 
et al. [30] compared the literature available on plant use for medicinal purposes across 
three distinct regions; Nepal, New Zealand and the Cape of South Africa.  
Regressional and binomial analyses were performed at a family level and resulted in 
the identification of several ‘hot’ families (Anacardiaceae, Asteraceae, 
Convolvulaceae, Clusiaceae, Cucurbitaceae, Euphorbiaceae, Geraniaceae, Lamiaceae, 
Malvaceae, Rubiaceae, Sapindaceae, Sapotaceae and Solanaceae).  In spite of many 
significant differences found across these three regions, the similarities may serve to 
indicate an underlying biological activity in the commonly used families. 
 
The prevention of chronic non-communicable diseases (like cancer, heart disease, 
Alzheimer’s, cataracts) remains an important area of research.  Tan et al. have used an 
ethnobotanical approach in the study of native Australian edible plants [31].  The 
significant decline in the health of the Aboriginal people has been attributed to dietary 
changes and the study of a number of their important foods has shown that they do 
possess some significant health benefits.  Some examples are wattle seeds (Acacia 
victoriae), which have shown strong anticancer, anti-inflammatory and anti-oxidant 
activity in animal models and the Illawarra plum fruit (Podocarpus elatus), which has 
shown anti-oxidant, and pro-apoptotic anti-cancer activity as well as the ability to 
reduce obesity in a mouse model.  Ethnobotanical data can provide useful information 
about the health enhancing as well as the disease preventing possibilities of 
traditionally used plants. 
 
The use of an ethnomedicinal approach combined with other tools can enhance the 
potential for success.  Bernard et al. [32] have shown that combining an 
ethnopharmacological with a bioinformatic approach can produce good results.  An 
ethnobotanical study of the Santarem region of Brazil identified 56 plants used locally 
as anti-inflammatories.   Plants found to be active on phospholipase A2 (an enzyme 
which plays a critical role in both the cyclooxygenase and 5-lipoxygenase 
inflammation pathways), were analysed using the NAPRALERT database and the 
Combined Chemical Library database to determine the known chemical constituents.  
Betulinic acid was found to be common and in addition could be inserted into the 
phospholipase A2 binding site with the correct energy values (-90kcal/mol).  Betulinic 
acid as well as betulin both showed good activity on phospholipase A2, as predicted 
by the bioinformatics information. 
 
The success of the ethnomedicinal approach can sometimes rest on the effectiveness 
of the extraction and testing methods employed.  Supercritical fluid extraction 
techniques can be tuned to allow for specific compound types to be selectively 
extracted, allowing for reduced clean up time.  Stenholm et al. [33] and Wang et al. 
[34] have demonstrated that supercritical fluid extraction can be tuned to extract 
previously determined bioactive components.  Stenholm et al. successfully 
preferentially extracted the COX-2 inhibitory substances -linolenic acid, ursolic acid 
and oleanolic acid from Plantago major L. while Wang et al. developed standard 
operating procedures for the extraction and identification of 
dibenzo[a,c]cyclooctadiene lignans from Schisandra chinensis Baill.  These are well 
known for their hepatoprotective, antioxidant and anticancer activity [34].  
Supercritical fluid extraction was successfully used by Sewram et al. [35-37] to 
effectively extract and identify the active components of three medicinally used South 
African plants.  Clivia miniata L., Grewia occidentalis L. and Ekebergia capensis 
Sparrm. are all used to facilitate labour in pregnant women.  Each was extracted using 
water modified supercritical carbon dioxide and the extracts were found to exhibit 
uterotonic activity.  By coupling a biological detector to the supercritical fluid 
extractor, active fractions could be immediately detected and active components could 
be isolated.  In the case of Grewia occidentalis, the extraction vessel was coupled 
directly to the bioassay being used (a muscle bath with guinea pig uterine muscle 
attached to a recorder).  The sample was extracted sequentially at three different 
pressures, 200, 300 and 400 atmospheres, with the 300 atmosphere extract 
immediately being identified as the most active [36].  The development of techniques 
that can be used to selectively extract specific compounds of interest are of huge 
benefit to ethnomedicinal plant studies and have the potential to increase the rate at 
which potentially interesting plants can be studied. 
 
The ecological approach  
 
Another non-random method of plant selection involves various ecologically based 
approaches.  Different authors have considered different aspects of the ecological 
argument, including the relationship between biodiversity and chemodiversity [8], the 
apparency theory [38, 39], the life-strategy theory [40], chemical defenses and 
herbivory [41], animal behavior [42] and phylogenetic trends [43, 44]. 
 
Ramesha et al. [8] have considered the relationship between biodiversity and 
chemodiversity.  Two models were suggested.  Firstly that chemodiversity increases 
linearly with biodiversity: that is that with an increase in biological diversity among 
taxa in question, the chemical diversity would also increase.  Secondly that initially a 
linear relationship is seen between chemical and biological diversity, but that a 
leveling off occurs.  This would imply that the number of chemical structures is finite.  
An example of this would be that with all the diversity in alkaloids, only 22 different 
scaffolds have been identified within the family Asteraceae, with the highest species 
diversity (21 000) producing only 14 of the 22.  The Fabaceae with 16 400 species, 
produces 17 of the identified 22 scaffolds.  The first model would suggest that 
bioprospecting in the widest possible way should lead to new bioactive chemical 
entities, while the second model would suggest that specific phylogenetic groups 
should be studied to enhance the probability of isolating a particular compound-type 
of interest [8].   
 
Zhu et al. [43] conducted a phylogenic study of the naturally-derived drugs approved 
between 1991 and 2010.  It was found that drug-productive species were clustered in 
specific phylogenic space.  It was suggested that a focus on untapped species 
belonging to already drug-productive families and clusters would increase the 
likelihood of discovering new useful bioactive compounds.  Saslis-Lagoudakis et al. 
[44] have linked ethnomedicinal use of the plants belonging to the genus Pterocarpus 
with specific nodes in the phylogeny.  They showed that species used to treat specific 
diseases, like malaria, tend to be phylogenetically clumped.  It could be assumed that 
closely related species would share a similar biochemistry and an understanding of 
phylogenetic relationships between plant species could facilitate plant selection for 
study. 
 
In order to defend themselves against herbivorous attack, plants have adopted a 
number of different strategies.  The apparency theory divides plants into two groups; 
those with a short life-cycle (herbs, annuals) that need to invest in small amounts of 
toxic chemicals to defend themselves (non-apparent) and those with a long life-cycle 
(apparent) who invest in quantitative, less toxic chemicals to reduce their digestibility 
[38].  This would suggest that traditional practitioners, as well as those prospecting 
for new bioactive compounds, should prefer non-apparent plants.  de Almeida et al. 
[38] [39] investigated whether the apparency theory could predict traditional 
medicinal practitioners’ choice of plants in the Caatinga and Atlantic Forest regions 
of northeast Brazil.  Neither habitat nor life-strategy were good predictors of 
phytochemical composition or plant selection in this region.  Albuquerque et al.[41] 
have considered both the apparency theory together with the resource-availability 
hypothesis.  In a resource-rich area, plants tend to be fast growing and tend to invest 
in rapid growth rather than in chemical defense.  Plants in resource-poor areas would 
invest more in chemical defenses and, as such, this makes these plant better 
candidates for investigation for biological activity.  Again the semi-arid Caatinga and 
the Atlantic Forest regions of Brazil were investigated.  They found that neither the 
apparency theory nor the resource availability hypothesis influenced the choice of 
plants by traditional medical practitioners.  Coley et al. [40] compared the defense 
strategies of mature and young leaves of plant collected throughout the protected 
wildlands of Panama.  They postulated that the young leaves would primarily employ 
chemical defense systems while the older, tougher leaves would to a lesser degree.  
Extracts of the fresh leaves were assessed using six in vitro bioassays (three cancer 
cell lines: breast MCF-7, lung H-460 and CNS SF-268; HIV and three tropical disease 
cell lines: Leishmania mexicana, Plasmodium falciparum and Chaga’s disease).  The 
young leaves showed greater activity than the mature leaves in almost all the 
bioassays used.  In a survey of 18 Panamanian woody species, 10 out of 18 species 
contained alkaloids only in the young leaves; only 3 species had unique mature leaf 
alkaloids.   It was further postulated that the mature leaves of slow growing shade-
tolerant species should display better chemical defenses than those fast growing 
species found in better-lit conditions.   The cost of replacing leaves in the resource 
poorer shady conditions would be greater.  The activity of these shade-tolerant mature 
leaves was comparable to the young leaves of the sun-loving plants.  In addition a 
strong phylogenetic signature was observed with some clades being more active than 
others. 
 
The observation of animal behaviour can sometimes provide insight into potential 
plant activity.  Khaya species are endemic to Africa and Madagascar.  Local people 
use the bitter bark and seeds to treat fevers and febrile conditions as well as microbial 
and worm infestations.  Baboons and chimpanzees in Western Uganda have been seen 
to eat the bark and seeds, which have no nutritional value and are bitter in taste [42].  
The petroleum extract of Khaya anthotheca showed good activity against 
Plasmodium falciparum K1 (IC50 = 0.955g/mL) and Trypanosoma brucei 
rhodesiense STIB 900 (IC50 = 5.72g/mL).  It would appear that in addition to there 
being evidence for the effectiveness of these plants as used by traditional healers, that 
the chimpanzees and baboons were using the seeds and bark to self-medicate [42]. 
 
Metabolomics 
 
Metabolomics is the study of the ‘global metabolite profile’ in a system under a given 
set of conditions’ [45]. While metabolomics does not help with the initial choice of 
plant to be studied, it can help with the rapid analysis of a plant extract and can give a 
good indication of the active constituents present in a particular extract.  
Metabolomics allows for the profiling of the entire metabolome or of specific 
fractions thereof before testing for biological activity. The concentrations and 
characteristics of the chemical constituents can be determined and statistical analysis 
(principal component analysis or partial least squares regression analysis) used to link 
compounds with physiological activity [46].  A problem commonly encountered with 
bioassay-guided fractionation is the loss of activity during fractionation.  An extract 
may contain a large amount of only moderately active compounds and so appear to be 
very active or it may contain very small amounts of highly active compounds.  
Synergistic interactions also need to be considered under such circumstances [47].  
The aim of metabolomics is to assess a complex mixture and in so doing allow for the 
identification of biologically active constituents without first isolating the compound 
involved [47].   
 
Metabolomics has proved useful in the analysis of the active constituents of herbal 
medicines. For example, Iino et al. [48] have used capillary electrophoresis time of 
flight mass spectrometry (CE-TOFMS) to analyse Toki-Shakuyaku-San, a Chinese 
medicine used for gynaecological and obstetric conditions.  They were able to identify 
737 ± 183.1 (average± standard deviation) metabolite-derived features, of which 119 
metabolites were identified [48]. The strength of the metabolomic approach when 
studying herbal medicines, is that it allows for the identification of all the compounds 
contributing to the medicinal effect of the plant and takes into account any synergism 
involved [49]. 
 
Albrecht et al. [50] have used liquid chromatography mass spectrometry (LC-MS) 
followed by principal component analysis and orthogonal least squares discriminant 
analysis to profile and distinguish between Sutherlandia frutescens plants growing in 
different regions of South Africa.  Clear differences in the metabolite profile were 
seen with implications for those in the herbal products industry utilizing Sutherlandia 
frutescens [50].  
 
Computational methods: virtual screening and reverse pharmacognosy 
 
Virtual screening (VS) makes use of the availability of large compound libraries 
generated by combinatorial and high throughput chemistry to select a small number of 
likely candidates for experimental testing [51].  Virtual screening can follow one or 
both of two general strategies: ligand-based virtual screening or structure-based 
virtual screening [51].  Ligand-based VS makes use of structural and biological 
activity information from known active compounds to select likely compounds for 
further testing.  Structure-based VS relies on knowledge of the 3-D structure of a 
molecule and uses techniques such as molecular docking (finding the best position 
and orientation of a compound within a binding site) to determine possible activity.  
With sufficient information about the activity and the 3-D structure of a compound, 
both techniques can be used and the likelihood of a hit increases substantially [51].  
The effectiveness of VS can sometimes be compromised by the number of 
approximations and assumptions that need to be made but still in some cases 
substantially (100-fold to 1000-fold) higher hit rates than high throughput screening 
have been noted [51].  Virtual screening techniques transform chemical databases 
from storage banks of compounds to useful tools in the drug discovery process and 
allow all the work already done and recorded to be fully exploited [52]. 
 
Decades of work in the field of pharmacognosy have resulted in a vast library of 
natural products, many of which have undergone only limited testing.  Reverse 
pharmacognosy aims to find new biological targets for natural products by either 
virtual or real screening and then to link these findings to either the original or another 
potential plant source [53].  This inverse method starts with the molecule and ends 
with the plant source.  This technique allows for the discovery of new biological 
activities from known natural compounds [54].  If a compound, available in large 
quantities from a renewable plant source is found to be active, both the use of the 
plant by local peoples is verified as well as the potential exploitation of the plant as a 
resource for development in a local community could be realized [55].  The research 
team at Greenpharma (France) have demonstrated the success of this technique with 
compounds like -viniferin (anti-inflammatory properties) [53], Merazin (COX-1, 
COX-2 and PPAR activity) [55] and honokiol (modulation of testosterone levels) 
[56] and the details of the technique have been well reviewed [54]. 
 
Conclusion 
 
All of the approaches discussed above have shown some success in the identification 
of plants containing biologically active compounds.  This success has not often led to 
the full development of a new commercial drug.  The improvement in high 
throughput screening techniques and the use of virtual screening methods to identify 
potential hits should be exploited fully to increase the likelihood of success.   Good 
collaboration between botanists, local traditional healers, chemists and 
pharmaceutical companies to ensure that potential hits are fully exploited is essential 
for progress.  The high cost of drug development from natural sources necessitates 
clever approaches in the initial discovery phase.  Utilizing a range of non-random 
approaches to plant choice can facilitate this, as can quicker and more effective 
methods of screening for activity.  A fuller application of the work already done in 
natural products, via processes like reverse pharmacognosy, can help to open up 
further avenues of potential success. 
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